by Jose Leal, 5th December 2025 Where should we build the next stage of our work? This question has been driving my thinking about the Gulf for the past year. As Ophiomics moves from clinical validation… Precision Diagnostics in Saudi Arabia? The beauty of Scale
Why Qatar can – and must – claim the diagnostics translation space before regional competitors occupy it By José Pereira Leal, PhD Published on Linkedin on Dec 4th, 2025. Over the past year, I’ve been… Qatar’s Precision Diagnostics Opportunity: From Research Excellence to Industry Leadership
Published on LinkedIn on Dec 1st, 2025 In the global race for medical innovation, market size matters, but market access matters more. Today, a medical device manufacturer targeting the Gulf Cooperation Council (GCC) faces a… The 60-Million+ Patient Passport: Why the GCC Needs a “Gulf CE Mark”
At 35, Sarah suffered a heart attack that a €30 genetic test could have prevented. Her story isn’t unusual, it’s a mirror of how health systems worldwide confuse “standard care” with equity. Sarah, a 34-year-old… Precision Medicine Isn’t Elitist: It’s the Only Equitable Option
Published on linkedin on June 17th 1. Not enough evidence! When we first embarked on developing Hepatopredict, our idea was very clear: create a biomarker-based test that could reliably inform clinical decisions about liver transplantation… From Promising to Proven: Lessons from the Validation Trenches of Biomarker Development